Company Overview

RNA as of 4:00 PM ET on 09/19/14
Price
8.66
Change
- 0.07
Day High
8.82
Day Low
8.54
20 minute delayed data provided by eSignal
Stock price graph
     

Prosensa is a biopharmaceutical company focused on the discovery, development and commercialization of RNA modulating therapeutics. The company targets genetic disorders with a large unmet medical need, with a primary focus on neuromuscular and neurodegenerative disorders such as Duchenne Muscular Dystrophy (DMD)Myotonic Dystrophy (DM1) and Huntington's Disease (HD).

Prosensa's portfolio of clinical and pre-clinical RNA-based drug candidates is currently focused on the treatment of DMD, with 6 programs currently in development. Prosensa’s lead candidate for the treatment of DMD, drisapersen, has completed Phase III clinical trials. 

Prosensa commenced operations in 2002 and is located in Leiden, The Netherlands. The company works closely together with academia, patient groups and experts worldwide. 

View all »   RSSRecent Releases

Sep 17, 2014
Prosensa announces commencement of re-dosing of drisapersen in North America in patients with Duchenne muscular dystrophy

Sep 9, 2014
Prosensa announces 12 presentations at the 19th International Congress of the World Muscle Society in Berlin

View all »Events & Presentations

Sep 26, 2014 at 9:00 AM
Prosensa at BioCentury NewsMakers